NextCure, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Michael S. Richman
- Full Time Employees
- 43
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 9000 Virginia Manor Road Beltsville MD United States of America 20705
- IPO Date
- May 9, 2019
- CIK
- 0001661059
- Website
- nextcure.com
- Similar Companies
- Business
- NextCure, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and advancing novel immunomedicines to treat cancer patients who do not respond to, or have disease progression on, current therapies. The company's core products include therapeutic candidates such as LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4 for the treatment of multiple solid tumors; NC410, a fusion protein of LAIR-2 designed to block immune suppression mediated by LAIR-1 and showing clinical activity in colorectal and ovarian cancers; and NC525, a monoclonal antibody targeting LAIR-1 focused on treating acute myeloid leukemia (AML) blast cells and leukemic stem cells. NextCure also pursues preclinical oncology and non-oncology programs leveraging its proprietary FIND-IOTM platform that identifies novel immune-oncology targets and biomarkers to develop therapies modulating immune responses in the tumor microenvironment. The company operates primarily in the United States from its headquarters in Beltsville, Maryland, and focuses on patients with cancer types inadequately addressed by existing therapies. Recent major developments include a strategic reprioritization in 2024 to advance the LNCB74 ADC program, with completion of the first cohort of a Phase 1 trial in early 2025 and plans to initiate backfill cohorts in the second half of the year. In 2025, NextCure formed a strategic partnership with Simcere Zaiming to advance a Phase 1 ADC program, SIM0505 (CDH6 ADC), acquiring global rights outside greater China and dosing the first U.S. patient in October 2025. The company successfully closed a private placement PIPE financing in November 2025, raising approximately $21.5 million to support its operational and clinical trial activities. NextCure aims to deliver proof-of-concept data for its key ADC programs, including LNCB74 and SIM0505, by the first half of 2026. The company continues to leverage its expertise in immune biology, antibody-drug conjugates, and biomarker-driven development as a strategy to address high unmet medical needs in oncology. Founded in 2015, NextCure maintains a focused pipeline predominantly in oncology immunotherapy and operates with around 40 employees. Its business segments include clinical oncology programs such as NC410, NC525, and LNCB74, combined with preclinical efforts targeting the tumor microenvironment and immune modulation. NextCure’s innovative approach integrates novel mechanisms of action, including immune checkpoint modulation and antibody-drug conjugates, to enhance immune response against cancer. The company remains committed to advancing its pipeline and strategic collaborations to expand its therapeutic offerings on a global scale.
NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
NextCure Provides Business Update and Reports First Quarter 2026 Financial Results
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
NextCure and Simcere's SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
NextCure Receives Fast Track Designation for SIM0505 (CDH6 ADC) in Ovarian Cancer
NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026
NextCure Provides Business Update and Reports Full Year 2025 Financial Results
NextCure Provides Business Update
Short Interest in NextCure, Inc. (NASDAQ:NXTC) Expands By 29.6%
Analyzing Monte Rosa Therapeutics (NASDAQ:GLUE) and NextCure (NASDAQ:NXTC)
NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference
NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts
NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules
Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?
NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
NextCure to Present at the H.C. Wainwright 27th Annual Global Investment Conference
NextCure (NXTC) Q2 Loss Widens 71%
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results